Neuropathy Affecting Patents (Class 514/18.2)
-
Publication number: 20130287755Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: April 28, 2011Publication date: October 31, 2013Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Patent number: 8557546Abstract: This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.Type: GrantFiled: May 23, 2011Date of Patent: October 15, 2013Assignee: Generon (Shanghai) CorporationInventors: Xiaoqiang Yan, Zhihua Huang, Hongzhou Yang, Bill N. C. Sun, Yuliang Huang
-
Patent number: 8551945Abstract: Disclosed herein are methods and compositions for treating neuropathies by modulating endogenous NT-3 of GDNF gene expression.Type: GrantFiled: February 4, 2010Date of Patent: October 8, 2013Assignee: Sangamo BioSciences, Inc.Inventors: Carolyn Dent, Josee Laganiere, Xiangdong Meng, David Paschon, Siyuan Tan, Lei Zhang, Steve H. Zhang
-
Publication number: 20130243745Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: June 1, 2011Publication date: September 19, 2013Applicants: ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Patent number: 8536130Abstract: Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.Type: GrantFiled: August 4, 2010Date of Patent: September 17, 2013Assignee: Gruenenthal GmbHInventors: Thomas Christoph, Elmar Friderichs, Babette-Yvonne Koegel, Murielle Meen
-
Publication number: 20130236440Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: May 3, 2011Publication date: September 12, 2013Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
-
Publication number: 20130236509Abstract: The invention relates to a biodegradable microparticle having a diameter between 0.2 and 3.5 micrometer and comprising a pharmaceutically effective amount of at least one small heat-shock protein that induces IL-10 production in macrophages, said small heat-shock protein comprising an amino acid sequence identity of at least 50% to any of the sequences listed as SEQ ID NOs: 1 and 12-26.Type: ApplicationFiled: July 14, 2011Publication date: September 12, 2013Applicant: DELTA CRYSTALLON B.V.Inventor: Johannes Maria Van Noort
-
Patent number: 8530424Abstract: A system and method to improve sensory functions in the hand or foot by dermal topical application of a local anaesthetic substance to adjacent skin areas, using a tailored application device or kit specially designed to fit the size and anatomical shape of the body part which is to be anesthetized. The concept is to block sensory input from the anesthetized skin area hereby inducing a functional reorganization in sensory brain cortex resulting in enhanced sensory functions in body parts adjacent to the anesthetized area with focus on the hand and sole of the foot.Type: GrantFiled: September 11, 2008Date of Patent: September 10, 2013Assignee: Ossur HFInventor: Göran Lundborg
-
Publication number: 20130230507Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: May 4, 2011Publication date: September 5, 2013Applicant: ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Alain Philippe Vasserot, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20130224174Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: July 12, 2011Publication date: August 29, 2013Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20130225498Abstract: There is provided a composition for preventing or treating neurodegenerative diseases, including one or two or more selected from the group consisting of a chemoattractant CCL5, a CCL5 expression regulator, and a CCL5 activator as an active ingredient, in which by confirming through a morris water maze task that the CCL5 recovers memory loss and improves spatial cognition ability, it has been found that the composition including any one or two or more selected from the group consisting of the CCL5, the CCL5 expression regulator, and the CCL5 activator can be usefully employed as a pharmaceutical composition or a food composition for preventing or treating neurodegenerative diseases.Type: ApplicationFiled: October 22, 2012Publication date: August 29, 2013Applicant: Kyungpook National University Industry-Academic Cooperation FoundationInventor: Kyungpook National University Industry-Academic
-
Patent number: 8518885Abstract: A novel class of peptide ?-ketoamides useful for selectively inhibiting calpains, selectively inhibiting cysteine proteases, and generally inhibiting all cysteine proteases, having the formula M-AA2-AA1-CO—NH—(CH2)n—R3. Processes for the synthesis of peptidyl ?-ketoamide derivatives. Compositions and methods for inhibiting cysteine proteases, inhibiting calpains, and treating disease caused by cysteine proteases and calpains are provided.Type: GrantFiled: July 16, 2008Date of Patent: August 27, 2013Assignees: Georgia Tech Research Corporation, Emory UniversityInventors: James C. Powers, Jonathan D. Glass, Asli Ovat, Zhaozhao Li
-
Publication number: 20130216539Abstract: The present invention includes methods of generating derivatives of a protein, as well as methods of treating a subject with the derivatized proteins. More particularly, the present invention includes methods of generating derivatives of HSP 70 proteins and methods of treating a subject with the derivatized HSP 70 proteins.Type: ApplicationFiled: February 15, 2013Publication date: August 22, 2013Applicant: ALS Biopharma, LLCInventor: ALS Biopharma, LLC
-
Patent number: 8513387Abstract: The invention provides binding proteins that bind to misfolded or monomeric SOD1, and not to native homodimeric SOD1. The invention also includes methods of diagnosing, detecting or monitoring amyotrophic lateral sclerosis in a subject. In addition, the invention provides methods of identifying substances for the treatment or prevention of amyotrophic lateral sclerosis and kits using the binding proteins of the invention.Type: GrantFiled: July 21, 2010Date of Patent: August 20, 2013Assignees: Amorfix Life Sciences Ltd., University Health NetworkInventors: Avijit Chakrabartty, Rishi Rakhit, Neil R. Cashman
-
Patent number: 8513197Abstract: Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the subject. This can involve administering to the subject a molecular mimic of a ganglioside that serves as a specific competitive inhibitor for anti-ganglioside antibodies in the circulation. Also disclosed is an animal model of GBS having anti-ganglioside antibodies in the circulation.Type: GrantFiled: July 31, 2012Date of Patent: August 20, 2013Assignee: Georgia Regents UniversityInventors: Robert Yu, Seigo Usuki
-
Patent number: 8507439Abstract: The invention relates to methods and products for preventing and treating neuronal cell death-associated diseases and/or conditions. The products and methods are useful for research and for clinical applications relating to neuronal cell-death associated diseases and/or conditions.Type: GrantFiled: August 28, 2006Date of Patent: August 13, 2013Inventor: Angela Shashoua
-
Publication number: 20130202576Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: July 12, 2011Publication date: August 8, 2013Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20130202575Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: May 12, 2011Publication date: August 8, 2013Applicants: PANGU BIOPHARMA LIMITED, aTyr Pharma, Inc.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, Zhiwen Xu, John D. Mendlein
-
Publication number: 20130202574Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: April 29, 2011Publication date: August 8, 2013Applicants: Pangu BioPharma Limited, aTyr Pharma, Inc.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry Dean Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
-
Patent number: 8501692Abstract: The present invention relates to compositions and methods for treating and preventing cocaine addiction. In particular, the present invention provides mutated cocaine esterase proteins for use in treating and preventing cocaine addiction.Type: GrantFiled: December 14, 2010Date of Patent: August 6, 2013Assignee: The Regents of the University of MichiganInventors: Roger K. Sunahara, John J. G. Tesmer, Diwahar Narasimhan, James H. Woods, Mark R. Nance, Elin Edwald
-
Publication number: 20130195832Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: May 3, 2011Publication date: August 1, 2013Applicants: PANGU BIOPHARMA LIMITED, a Tyr Pharma, Inc.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
-
Publication number: 20130196926Abstract: Described herein are bioresponsive protein polymers for therapeutic applications, including delivery to physiologically demanding environments, such as the eye surface. Bioresponsive protein polymers can be fused with biopharmaceuticals using genetic engineering techniques for enhanced therapeutic activity. In certain embodiments, the unique temperature-sensitive phase separation properties of bioresponsive protein polymers, allows generation of therapeutics resistant to ocular clearance. Such fusion proteins containing bioresponsive protein polymers and biopharmaceuticals allow retention of drugs in the eye for much longer periods of time.Type: ApplicationFiled: July 26, 2012Publication date: August 1, 2013Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: John Andrew MacKay, Wan Wang
-
Publication number: 20130190223Abstract: The compounds of the present invention are non-immunosupressive cyclosporine analogue molecules that are able to bind cyclophilin. Said compounds include a modified side chain of amino acid I of cyclosporin A, consisting of an oxyalkyl having substituents R?, R1 and R2, where R? is H or Acetyl; R1 is a saturated or unsaturated straight chain or branched aliphatic carbon chain; and R2 may be a hydrogen; a unsubstituted, N substituted or NN disubstituted amide; a N substituted or unsubstituted acyl protected amine; a carboxylic acid; a N substituted or unsubstituted amine; a nitrile; a ester; a ketone; a hydroxy, dihydroxy, trihydroxy or polyhydroxy alkyl; or a substituted or unsubstituted aryl.Type: ApplicationFiled: July 3, 2009Publication date: July 25, 2013Applicant: ISOTECHNIKA PHARMA INC.Inventors: Alexander Hegmans, Bruce W. Fenske, David P. Czajkowski, Darren R. Ure, Shin Sugiyama, Dan J. Trepanier, David H. McGlade, Mark D. Abel
-
Patent number: 8492336Abstract: There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid sequence from position 27 to 139 of the sequence illustrated in FIG. 1, or a functional equivalent, derivative or bioprecursor thereof. The nucleic acid molecule encoding enovin can be used to transform a host cell, tissue or organism by including it in an appropriate vector. The host cell, tissue or organism and the vector also form part of the invention.Type: GrantFiled: December 21, 2010Date of Patent: July 23, 2013Assignee: Janssen Pharmaceutica N.V.Inventor: Stefano Leo Jozef Masure
-
Patent number: 8481067Abstract: The present invention provides methods of promoting the revascularization and/or reenervation of central nervous system lesions using an in-situ crosslinkable hydrogel.Type: GrantFiled: June 4, 2010Date of Patent: July 9, 2013Assignee: Clemson University Research FoundationInventors: Ning Zhang, Xuejun Wen
-
Patent number: 8465727Abstract: Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein (CRP), cystatin c, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH). The sample is typically cerebral spinal fluid (CSF). The levels or concentrations of the biomarkers can be used to determine the onset of ALS, monitor the progression of ALS, or monitor the progression of a treatment for ALS.Type: GrantFiled: October 6, 2010Date of Patent: June 18, 2013Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventor: Robert P. Bowser
-
Publication number: 20130102538Abstract: The present invention relates to a method for treating an individual having Alzheimer's Disease by using pharmacological chaperones that bind presenelin and thereby increase ?-secretase activity.Type: ApplicationFiled: May 4, 2011Publication date: April 25, 2013Applicant: AMICUS THERAPEUTICS, INC.Inventors: Brandon Wustman, Anthony Stevens
-
Publication number: 20130072421Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.Type: ApplicationFiled: January 13, 2011Publication date: March 21, 2013Applicant: CURNA, INCInventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
-
Publication number: 20130053321Abstract: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.Type: ApplicationFiled: May 14, 2012Publication date: February 28, 2013Inventors: Daria Mochly-Rosen, Xin Qi, Nir Qvit
-
Patent number: 8377875Abstract: The invention is based on the discovery of a novel neuroprotective peptide. In addition, the invention rests on the discovery that the NAP peptide enhances the association of tau and the brain-specific beta tubulin subunit. In addition, NAP modifies microtubule assembly and dynamics, in part, by affecting the tyrosination of microtubule proteins. The invention provides compositions and methods for treatment and prevention of neuronal disorders, including NAP-binding and tau-binding agents, tau peptide mimetics, NAP-like and NAP-like tau peptide mimetics.Type: GrantFiled: January 10, 2008Date of Patent: February 19, 2013Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Illana Gozes, Maya Maor, Saar Oz, David Dangoor, Inna Divinski
-
Publication number: 20130005645Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.Type: ApplicationFiled: January 6, 2011Publication date: January 3, 2013Inventors: Michael P. VITEK, Dale J. Christensen
-
Patent number: 8338378Abstract: The present invention relates to a neurotrophic peptide having an amino acid sequence selected from the group consisting of VGDGGLFEKKL (SEQ ID NO: 1), EDQQVHFTPTEG (SEQ ID NO: 2) and IPENEADGMPATV (SEQ ID NO: 3).Type: GrantFiled: March 17, 2008Date of Patent: December 25, 2012Assignee: Research Foundation For Mental Hygiene, Inc.Inventors: Herbert Mossler, Khalid Iqbal, Inge Grundke-Iqbal
-
Patent number: 8338641Abstract: The present invention is directed to the use of a class of peptide compounds for treating pain in trigeminal neuralgia.Type: GrantFiled: June 16, 2010Date of Patent: December 25, 2012Assignee: UCB Pharma GmbHInventors: Thomas Stöhr, Christine Rauschkolb-Loeffler
-
Patent number: 8334263Abstract: Compositions of flupirtine for management of neuropathic or inflammatory pain optionally including one or more other analgesics including opiates, NSAIDS and other active agents in immediate and controlled release forms. Methods and systems for administration of these compositions.Type: GrantFiled: December 16, 2004Date of Patent: December 18, 2012Inventors: Raymond Nadeson, Adam Paul Tucker, Colin Goodchild
-
Patent number: 8333974Abstract: The present invention provides effective dosing regimes for neural stem cell proliferating agents, kits containing effective dosing regimes for neural stem cell proliferating agents, and uses thereof. In particular, neural stem cell proliferating agents, such as hCG, prolactin and EPO are delivered to mammalian subjects at low doses in a continuous fashion over several days, as opposed to delivery of high doses in a short period of time.Type: GrantFiled: March 16, 2007Date of Patent: December 18, 2012Assignee: Stem Cell Therapeutics Corp.Inventors: Samuel Weiss, Christopher Gregg, Allen Davidoff, Joseph Tucker
-
Patent number: 8334264Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.Type: GrantFiled: July 7, 2009Date of Patent: December 18, 2012Assignee: NsGenee A/SInventors: Jesper Roland Jørgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
-
Patent number: 8309684Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: GrantFiled: April 6, 2010Date of Patent: November 13, 2012Assignee: Curonz Holdings Company LimitedInventors: Paul William Richard Harris, Margaret Anne Brimble, Frank Sieg
-
Publication number: 20120270777Abstract: The present invention relates generally to the field of neuronal health and neuronal protection. One embodiment of the present invention relates to a composition that can be used for the protection of the enteric nervous system from neurodegeneration. Disorders linked to an impaired enteric nervous system can be treated or prevented by the administration of lactoferrin containing compositions according to the present invention.Type: ApplicationFiled: May 7, 2010Publication date: October 25, 2012Applicant: NESTEC S.A.Inventors: Magali Faure, Bing Wang, Jeroen Schmitt
-
Publication number: 20120264682Abstract: Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO; methods for treating or preventing a disease or disorder using tissue protective peptides; and methods for enhancing excitable tissue function using tissue protective peptides.Type: ApplicationFiled: April 16, 2012Publication date: October 18, 2012Applicant: Araim Pharmaceuticals, Inc.Inventors: Anthony CERAMI, Michael Brines, Thomas Coleman
-
Publication number: 20120237552Abstract: Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK/JNK phosphorylation to various extents in both cell lines.Type: ApplicationFiled: August 31, 2010Publication date: September 20, 2012Inventors: Beatriz Moreno, Pablo Villoslada, Joaquin Messeguer, Gloria Navarro, Angel Messeguer
-
Publication number: 20120230979Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.Type: ApplicationFiled: March 7, 2012Publication date: September 13, 2012Applicant: Biogen Idec MA Inc.Inventors: Sha MI, John McCoy, R. Blake Pepinsky, Daniel H.S. Lee
-
Publication number: 20120214731Abstract: The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a culture broth, a pharmaceutical composition containing the compound, and uses of the compound.Type: ApplicationFiled: January 19, 2012Publication date: August 23, 2012Inventors: Takanao Otsuka, Hirotsugu Ueda, Keiko Fujie, Hideyuki Muramatsu, Michizane Hashimoto, Shigehiro Takase
-
Publication number: 20120208747Abstract: Disclosed are peptides for augmenting the expression of BDNF (brain-derived neurotrophic factor) and a pharmaceutical composition for the prevention and treatment of Alzheimer's disease or Parkinson's disease, comprising the same. The peptides can induce the expression of BDNF in dopamine-reactive human cells, pass easily through the blood-brain barrier thanks to their low molecular weights and are almost free of cytotoxicity. Thus, they are useful in the prevention and treatment of neuropathies such as Alzheimer's disease or Parkinson's disease.Type: ApplicationFiled: December 31, 2009Publication date: August 16, 2012Applicant: SUNGYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATIONInventors: Kil Lyong Kim, Hong Gi Kim, Woo Ram Jung, Dong Ik Park, Min Kyoo Shin
-
Publication number: 20120208743Abstract: The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).Type: ApplicationFiled: April 25, 2012Publication date: August 16, 2012Inventors: Thomas P. STOSSEL, Teresia Anna Charlotta Magnuson Osborn, Andrej Tarkowski, Erlc Leuchovius
-
Patent number: 8236765Abstract: Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the subject. This can involve administering to the subject a molecular mimic of a ganglioside that serves as a specific competitive inhibitor for anti-ganglioside antibodies in the circulation. Also disclosed is an animal model of GBS having anti-ganglioside antibodies in the circulation.Type: GrantFiled: May 27, 2010Date of Patent: August 7, 2012Assignee: Medical College of Georgia Research Institute, Inc.Inventors: Robert Yu, Seigo Usuki
-
Patent number: 8227408Abstract: The present invention relates to methods for treating, preventing, or diagnosing the pathology of progressive cognitive disorders resulting from accumulation of an amyloid peptide, in particular, Alzheimer's disease, Down's syndrome and cerebral amyloid angiopathy, in mammalian subjects using a composition comprising therapeutically effective amount of a leptin, leptin mimic, leptin derivative, leptin agonist, or AMP-dependent protein kinase activator, alone, or in combination with, one or more lipolytic/antilipogenic compounds. It further relates to methods for improving cognitive function using a composition comprising a therapeutically effective amount of leptin, a leptin mimic, a leptin derivative, an AMP-dependent protein kinase activator, a leptin agonist, a leptin blocker, a mimic of a leptin blocker, a leptin antagonist, an AMP-dependent protein kinase inhibitor; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 6, 2006Date of Patent: July 24, 2012Assignee: Neurotez, Inc.Inventor: Nikolaos Tezapsidis
-
Patent number: 8227416Abstract: Disclosed herein are an agent for treating traumatic peripheral nerve injury comprising a granulocyte colony stimulating factor (G-CSF) as an active ingredient and a method for treating traumatic peripheral nerve injury with the same. The therapeutic agent advantageously regenerates nerve cells and blood vessels in peripheral nerve tissues and thus rehabilitates the injured nerve tissues to improve nerve conduction velocity, and relieves pain induced by traumatic peripheral nerve injury.Type: GrantFiled: March 20, 2009Date of Patent: July 24, 2012Assignee: Industry-University Cooperation Foundation, Hanyang UniversityInventors: Kyung-Soo Kim, Jun-Ho Joe
-
Publication number: 20120184492Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: December 15, 2011Publication date: July 19, 2012Applicant: NsGene A/SInventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg
-
Publication number: 20120178676Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.Type: ApplicationFiled: May 17, 2011Publication date: July 12, 2012Applicant: CEBIX, INC.Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni
-
Patent number: 8217146Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: GrantFiled: December 7, 2009Date of Patent: July 10, 2012Assignees: Biogen Idec MA Inc., NsGene A/SInventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando